The transaction accelerates the expiration of biosimilars non-compete restrictions, the company said. The shares are subject to a six-month lock up period. Transaction value will be subject to related ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. The Viatris stake is one of ...

Biocon has announced that it is to fully integrate Biocon Biologics Limited Biocon share price is in focus today after the company announced a major restructuring move involving its biologics business ...

Viatris (VTRS) on Saturday said that it has entered into definitive agreements with Biocon for the sale of Viatris' equity stake in Biocon Biologics Limited. Under the definitive agreements, Biocon ...

I write about Asia's richest, fast-growing businesses, and startups. Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon ...

BENGALURU: Indian biopharmaceutical company Biocon says it would fully integrate its biosimilar unit Biocon Biologics as a wholly owned subsidiary, consolidating Biocon’s biosimilars and generics ...

Biotechnology major Biocon on Saturday (December 6, 2025) said it will fully integrate Biocon Biologics with itself, in a deal valuing the biologics unit at $5.5 billion. As part of the transaction, ...

Bengaluru-headquartered biopharmaceutical major Biocon has announced that it is to fully integrate Biocon Biologics Limited (BBL) as a wholly owned subsidiary into Biocon Limited. Describing it as a ...

Biocon Limited’s board on December 6 approved a plan to fully integrate Biocon Biologics Limited (BBL) into the parent company and to raise fresh capital to fund the cash portion of the deal. The ...

Biocon Ltd will integrate Biocon Biologics Ltd as a wholly owned subsidiary in a deal valuing the unit at $5.5 billion, the company said on Saturday. Biocon will acquire the remaining stake in Biocon ...

Biocon on Saturday announced that it will fully integrate its biosimilars arm Biocon Biologics Limited (BBL) into the parent company. The company said the move is aimed at creating a unified biopharma ...

Biopharma major Biocon has consolidated its wholly-owned subsidiary, Biocon Biologics Limited (BBL), into Biocon Limited, with the integration expected to be completed by March 31, 2026. Biocon ...